Biologics for the Treatment of Rheumatoid Arthritis

1. Front Matter

   Pages I-XIII

   PDF

2. Disease overview

   • Ronald F. van Vollenhoven

   Pages 1-8

3. General Treatment Aspects

   • Ronald F. van Vollenhoven

   Pages 9-27

4. Overview of Biologic Therapies

   • Ronald F. van Vollenhoven

   Pages 29-38

5. Cytokine inhibitors

   • Ronald F. van Vollenhoven

   Pages 39-69

6. B-cell Directed Therapy

   • Ronald F. van Vollenhoven

   Pages 71-78

7. T-cell Directed Therapy

   • Ronald F. van Vollenhoven

   Pages 79-82

8. Novel biologics and small molecules with biologic-like effects

   • Ronald F. van Vollenhoven

   Pages 83-91

9. Strategies for the optimal use of biologic agents in rheumatoid arthritis

   • Ronald F. van Vollenhoven

   Pages 93-107

10. Considerations for special patient populations

    • Ronald F. van Vollenhoven

    Pages 109-121

11. Conclusions and future outlook

    • Ronald F. van Vollenhoven

    Pages 123-132

This book provides a comprehensive overview of the available biologic therapies whilst comparing them to standard disease modifying anti-rheumatic drugs, and discusses how best to determine which therapy is most appropriate for an individual patient in the framework of current guidelines. Biologics for the Treatment of Rheumatoid Arthritis is an up-to-date and concise practical guide to the latest therapeutic developments in this field. This book is an invaluable source of topical information for all rheumatologists and health care professionals treating patients with rheumatoid arthritis.

• Biologics
• Immunology
• Inflammatory rheumatic disease
• Rheumatoid arthritis
• Rheumatology

• Unit for Clinical Therapy Research, Karolinska University Hospital, Stockholm, Sweden

  Ronald F van Vollenhoven

Professor Ronald F van Vollenhoven is Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute, and of the Clinical Trials Unit Rheumatology at the Karolinska University Hospital. He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by a residency (specialty training) in internal medicine at the State University of New York at Stony Brook, and a fellowship in rheumatology at Stanford University in Palo Alto following which he received American Board of Internal Medicine certification in both internal medicine and rheumatology. From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 Professor van Vollenhoven moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; and in 2010, he was appointed in his current position as Professor and Unit Chief at the Karolinska Institute.

Professor van Vollenhoven’s research interests focus around the development and systematic evaluation of biologic and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he has established the Stockholm registry for biological therapies (the STURE database) for this purpose, which has supported research projects relating to clinical efficacy, pharmacology, outcomes, and pharmacoeconomics. He has been principal investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT trial. He has published over 240 original papers, book chapters and reviews, and is Editor of the textbook Targeted Treatment of the Rheumatic Diseases and associate-editor of Dubois’ Lupus Erythematosus. In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatology societies. He is the Editor-in-Chief of Lupus Science & Medicine, Chair of the EULAR Standing Committee on Clinical Affairs, member of many editorial boards, past-chair of the Swedish Rheumatology Society Professors’ Council, co-founder of the IRBIS registry for biologics in systemic lupus erythematosus (SLE), the CERERRA registries collaboration, and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE initiative. Professor van Vollenhoven lives just north of Stockholm with his wife and children aged 20 and 16. Outside his professional life he is an avid classical pianist.

Policies and ethics